For research use only. Not for therapeutic Use.
Sivopixant (S-600918) is a potent and selective P2X3 receptor antagonist (P2X3 IC50=4.2 nM; P2X2/3 IC50=1100 nM). Sivopixant shows strong analgesic effect[1].
Sivopixant (S-600918) (i.v.;1 mg/kg) shows a longer half-life (T1/2= 10.1 hours) and a strong analgesic effect in the rat Seltzer model of allodynia (ED50=0.4 mg/kg)[1].
| Catalog Number | I036321 |
| CAS Number | 2414285-40-6 |
| Synonyms | (2S)-3-[3-[(4-chlorophenyl)methyl]-2,6-dioxo-4-(4-pyridin-2-yloxyanilino)-1,3,5-triazin-1-yl]-2-methylpropanoic acid |
| Molecular Formula | C25H22ClN5O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H22ClN5O5/c1-16(22(32)33)14-31-24(34)29-23(30(25(31)35)15-17-5-7-18(26)8-6-17)28-19-9-11-20(12-10-19)36-21-4-2-3-13-27-21/h2-13,16H,14-15H2,1H3,(H,32,33)(H,28,29,34)/t16-/m0/s1 |
| InChIKey | SKZQFKBIJUXXCG-INIZCTEOSA-N |
| SMILES | CC(CN1C(=O)N=C(N(C1=O)CC2=CC=C(C=C2)Cl)NC3=CC=C(C=C3)OC4=CC=CC=N4)C(=O)O |
| Reference | [1]. Kai H, et al. Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists [published online ahead of print, 2021 Sep 26]. Bioorg Med Chem Lett. 2021;52:128384. |
